insights_auto
Outlook: 53.3% bullish·6.7% bearish
Go to analysischevron_right
GSK:NYSE
GSK plc
USD 50,06
arrow_downward
-1,13%(-0,57) 1D
21 Okt., 11:57:51 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
USD 50,19
High
USD 50,44
Low
USD 49,91
Mkt. cap
99,42 mjd
Avg. vol.
4,83 m
Volume
1,30 m
Dividend
3,63%
Quarterly dividend
USD 0,45
Ex-dividend date
13 Aug. 2026
P/E ratio
15,86
52-wk high
USD 61,70
52-wk low
USD 42,84
EPS
USD 3,16
Beta
0,25
Shares outstanding
2,16 mjd
No. of employees
67 k
Open
USD 50,19
High
USD 50,44
Low
USD 49,91
Mkt. cap
99,42 mjd
Avg. vol.
4,83 m
Volume
1,30 m
Dividend
3,63%
Quarterly dividend
USD 0,45
Ex-dividend date
13 Aug. 2026
P/E ratio
15,86
52-wk high
USD 61,70
52-wk low
USD 42,84
EPS
USD 3,16
Beta
0,25
Shares outstanding
2,16 mjd
No. of employees
67 k
News stories
From web sources and news partners
Benzinga
·
1 uur gelede
GSK Wins FDA Approval For Chronic Hepatitis B Drug
Zacks
·
2 uur gelede
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
Yahoo Finance
·
2 uur gelede
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8 k
Founded27 Des. 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com